Are you over 18 and want to see adult content?
More Annotations
A complete backup of dubaicurtains.com
Are you over 18 and want to see adult content?
A complete backup of kharkovestate.com
Are you over 18 and want to see adult content?
A complete backup of minniedeer.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of beautifullycustom.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://anthonyguennegou.fr
Are you over 18 and want to see adult content?
A complete backup of https://bonhommedebois.com
Are you over 18 and want to see adult content?
A complete backup of https://shoppingchase.com
Are you over 18 and want to see adult content?
A complete backup of https://waukeganweb.net
Are you over 18 and want to see adult content?
A complete backup of https://mintrans.gov.by
Are you over 18 and want to see adult content?
A complete backup of https://net-miyagi.com
Are you over 18 and want to see adult content?
A complete backup of https://myket.ir
Are you over 18 and want to see adult content?
A complete backup of https://homebusinessonline.com
Are you over 18 and want to see adult content?
A complete backup of https://typhoon2000.ph
Are you over 18 and want to see adult content?
A complete backup of https://clarityenglish.com
Are you over 18 and want to see adult content?
A complete backup of https://geoffreybawa.com
Are you over 18 and want to see adult content?
A complete backup of https://tradinghours.com
Are you over 18 and want to see adult content?
Text
31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of FOUR STEPS TO BUILD TRUST IN COVID-19 VACCINES The following four steps can build trust in these vaccines. First, before the end of September the FDA should make public its new detailed guidance on emergency use authorization for COVID-19 vaccines. Thus, public discussion could occur before any company files for an EUA for their COVID-19 vaccine candidate. SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. MODERNA TO TEST A “MULTIVALENT” COVID VACCINE AS WELL AS By Daniel R. Lucey MD, MPH, FIDSA. On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines mRNA-1273, Moderna’s authorized WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
HAS TESTING OF HUMANS FOR ASYMPTOMATIC AND MILD H5N8 BIRD Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to FOUR PROBLEMS WITH THE LAB ORIGIN HYPOTHESIS OF SARS-COV-2 By Daniel R. Lucey MD, MPH, FIDSA. Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website. Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of FOUR STEPS TO BUILD TRUST IN COVID-19 VACCINES The following four steps can build trust in these vaccines. First, before the end of September the FDA should make public its new detailed guidance on emergency use authorization for COVID-19 vaccines. Thus, public discussion could occur before any company files for an EUA for their COVID-19 vaccine candidate. SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. MODERNA TO TEST A “MULTIVALENT” COVID VACCINE AS WELL AS By Daniel R. Lucey MD, MPH, FIDSA. On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines mRNA-1273, Moderna’s authorized WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
HAS TESTING OF HUMANS FOR ASYMPTOMATIC AND MILD H5N8 BIRD Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to WHO WE ARE | SCIENCE SPEAKS: GLOBAL ID NEWS HIV As substance use disorders rise in the midst of a pandemic, a new law is needed now to facilitate treatment. While America’s epidemic of opioid use was already a burgeoning health crisis, it has worsened markedly since the onset of the COVID-19 pandemic. COVID MULTIVALENT VACCINES FOR MULTIVARIANT VIRUSES Instead, it will be their first dose of a COVID-19 vaccine. The Jan. 28 Novavax synopsis of its 4,400-person adjuvanted protein vaccine study in South Africa included the statement (in boldtype below) that 1/3 of those enrolled had antibody evidence of a prior non-variant SARS-CoV-2 infection, and that some had been re-infected with thevariant
AS ENVIRONMENTAL DESTRUCTION ACCELERATES THE SPREAD OF John Bruch August 15, 2020 at 3:59 pm. Overpopulation is the cause of the environmental destruction that leads to pandemics. Only a worldwide one-child policy can ameliorate the need for economic growth, which is inherently destructive (there is WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even BIVALENT COVID VACCINES: WHEN WILL STUDIES BEGIN IN ORDER By Daniel R. Lucey MD, MPH, FIDSA. The New York Times reported Monday (Jan. 25) that: “As a precaution, Moderna has begun developing a new form of its vaccine that could be used as a booster shot against the variant in South Africa . . . Moderna said it also planned to begin testing whether giving patients a third shot of its original vaccine as a booster could help fend off newly emerging COVID-19: WHEN WILL FDA CONVENE AN INDEPENDENT ADVISORY By Daniel R. Lucey M.D., MPH, FIDSA. Rapidly evolving events regarding studies of monoclonal antibodies reemphasize the call first made here Oct. 19 that the U.S. Food and Drug Administration convene an outside expert advisory committee ASAP to advise on requests for Emergency Use Authorization for monoclonal antibodies against SARS-CoV-2.. On Oct. 7 Lilly announced filing COVID-19: A DOCTOR EXPLORES PREPAREDNESS IN GHANA A beast is on the loose. A disease named COVID-19. Wall Street has eyes on the beast and its potential to turn a bull market into a bear market. Like a beast with a fire-lit tail it is going from country to country lighting up fires that devour human lives. The smoke of symptoms of infected patients is the first clue about its presence. AS VARIANT B.1.427/B.1.429 SPREADS IN CALIFORNIA, NEVADA Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. BREAKING: WHO ISSUES NEW GUIDANCE FOR DISCORDANT COUPLES The World Health Organization released its new “Guidance on couples HIV testing and counselling, including antiretroviral therapy (ART) for treatment and prevention in serodiscordant couples: Recommendations for a public health approach” on Wednesday. Discordant couples are those where one partner is HIV-infected and the other is not, where a couple is defined as two persons in an ongoing SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to FOUR PROBLEMS WITH THE LAB ORIGIN HYPOTHESIS OF SARS-COV-2 By Daniel R. Lucey MD, MPH, FIDSA. Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website. Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of FOUR STEPS TO BUILD TRUST IN COVID-19 VACCINES The following four steps can build trust in these vaccines. First, before the end of September the FDA should make public its new detailed guidance on emergency use authorization for COVID-19 vaccines. Thus, public discussion could occur before any company files for an EUA for their COVID-19 vaccine candidate. SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. 2019-NCOV: A SECOND EVIDENCE-BASED HYPOTHESIS 2019-nCoV: A second evidence-based hypothesis. By IDSA Contributor on January 30, 2020. Dr. Daniel Lucey, who has responded to, and monitored information on outbreaks since 2001, has provided a series of updates and analysis on the outbreak, now an epidemic of 2019-nCoV, the novel coronavirus identified in Wuhan China, since Jan. 7. UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
VIRTUAL CROI 2021: FROM COVID-19 TESTING TO DEATH, TOLL OF This entry was posted in Covid-19/2019-nCoV, Virtual CROI 2021 on March 9, 2021. Post navigation ← Virtual CROI 2021: Disparate impacts of two pandemics highlight systemic and leadership failures across four decades Virtual CROI 2021: On-site HIV testing from traditional healers raises diagnoses, links to care → VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
HAS TESTING OF HUMANS FOR ASYMPTOMATIC AND MILD H5N8 BIRD Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to FOUR PROBLEMS WITH THE LAB ORIGIN HYPOTHESIS OF SARS-COV-2 By Daniel R. Lucey MD, MPH, FIDSA. Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website. Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of FOUR STEPS TO BUILD TRUST IN COVID-19 VACCINES The following four steps can build trust in these vaccines. First, before the end of September the FDA should make public its new detailed guidance on emergency use authorization for COVID-19 vaccines. Thus, public discussion could occur before any company files for an EUA for their COVID-19 vaccine candidate. SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. 2019-NCOV: A SECOND EVIDENCE-BASED HYPOTHESIS 2019-nCoV: A second evidence-based hypothesis. By IDSA Contributor on January 30, 2020. Dr. Daniel Lucey, who has responded to, and monitored information on outbreaks since 2001, has provided a series of updates and analysis on the outbreak, now an epidemic of 2019-nCoV, the novel coronavirus identified in Wuhan China, since Jan. 7. UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
VIRTUAL CROI 2021: FROM COVID-19 TESTING TO DEATH, TOLL OF This entry was posted in Covid-19/2019-nCoV, Virtual CROI 2021 on March 9, 2021. Post navigation ← Virtual CROI 2021: Disparate impacts of two pandemics highlight systemic and leadership failures across four decades Virtual CROI 2021: On-site HIV testing from traditional healers raises diagnoses, links to care → VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
HAS TESTING OF HUMANS FOR ASYMPTOMATIC AND MILD H5N8 BIRD Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to MODERNA TO TEST A “MULTIVALENT” COVID VACCINE AS WELL AS By Daniel R. Lucey MD, MPH, FIDSA. On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines mRNA-1273, Moderna’s authorized VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
COVID VACCINES IN HIV-POSITIVE RECIPIENTS: NEED FOR MORE By Daniel R. Lucey MD, MPH, FIDSA. The Jan. 28 Novavax press release that included preliminary results from its COVID-19 vaccine Phase 2b trial in South Africa appears to contain a significant difference in efficacy between volunteers who were HIV-positive and HIV-negative. If verified, then the implications warrant sustained attention for this protein-based adjuvanted COVID-19 vaccine, COVID-19: WHEN WILL FDA CONVENE AN INDEPENDENT ADVISORY By Daniel R. Lucey M.D., MPH, FIDSA. Rapidly evolving events regarding studies of monoclonal antibodies reemphasize the call first made here Oct. 19 that the U.S. Food and Drug Administration convene an outside expert advisory committee ASAP to advise on requests for Emergency Use Authorization for monoclonal antibodies against SARS-CoV-2.. On Oct. 7 Lilly announced filing COVID-19: DOES THE MULTISYSTEM INFLAMMATORY SYNDROME IN On Saturday, the World Health Organization released a scientific brief on the multisystem inflammatory syndrome seen in children and adolescents with COVID-19.Today in Science Speaks two guest posts respond to findings around the syndrome. The following is a guest post Daniel R. Lucey M.D., MPH and Kristen R. Kent, MPhil. WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even COVID-19: CDC REPORTS ISSUE WITH REAGENT USED IN PCR TEST 2 thoughts on “ Covid-19: CDC reports issue with reagent used in PCR test sent to states and overseas — a Q&A ” Ozlem Equils, MD, FAAP February 28, 2020 at 5:40 pm. I am a past Associate Professor of Pediatric Infectious Diseases at Cedars-Sinai Med Ctr/UCLA, Chair of Adolescent Immunization Committee at the Immunization Coalition of LA County, member of Pediatric Infectious AN ID PHYSICIAN ADDRESSES QUESTIONS ON PNEUMONIA OF Q & A: Pneumonia Outbreak in Wuhan City, China. Daniel Lucey M.D. MPH, is an infectious diseases physician and adjunct professor of infectious diseases at Georgetown University Medical Center, a senior scholar at the Georgetown University O’Neil Institute, Anthropology Research Associate, Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America LOWER AGE OF CONSENT FOR HIV TESTING LINKED TO HIGHER Sub-Saharan African countries where adolescents 15 or younger could be tested for HIV without sign-off by parents or guardians show 11 percent higher rates of testing for the virus among those from 15 to 18 years old than in countries where the legal age of consent for testing is 16 or older, according to a study published in the World Health Organization’s January Bulletin. SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to FOUR PROBLEMS WITH THE LAB ORIGIN HYPOTHESIS OF SARS-COV-2 By Daniel R. Lucey MD, MPH, FIDSA. Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website. Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
FOUR STEPS TO BUILD TRUST IN COVID-19 VACCINES The following four steps can build trust in these vaccines. First, before the end of September the FDA should make public its new detailed guidance on emergency use authorization for COVID-19 vaccines. Thus, public discussion could occur before any company files for an EUA for their COVID-19 vaccine candidate. MODERNA TO TEST A “MULTIVALENT” COVID VACCINE AS WELL AS By Daniel R. Lucey MD, MPH, FIDSA. On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines mRNA-1273, Moderna’s authorized WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
DR. JOHN G. BARTLETT LOOKS BACK ON AIDS: A 30-YEAR By Meredith Mazzotta on May 31, 2011. Dr. John G. Bartlett when he first joined Johns Hopkins in 1980. HIV specialist and leading infectious diseases physician John G. Bartlett, MD, doesn’t mince words when you ask him about what his AIDS patients faced in the early days of the epidemic. “They were the scourge of society – peopledidn’t
SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to FOUR PROBLEMS WITH THE LAB ORIGIN HYPOTHESIS OF SARS-COV-2 By Daniel R. Lucey MD, MPH, FIDSA. Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website. Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
FOUR STEPS TO BUILD TRUST IN COVID-19 VACCINES The following four steps can build trust in these vaccines. First, before the end of September the FDA should make public its new detailed guidance on emergency use authorization for COVID-19 vaccines. Thus, public discussion could occur before any company files for an EUA for their COVID-19 vaccine candidate. MODERNA TO TEST A “MULTIVALENT” COVID VACCINE AS WELL AS By Daniel R. Lucey MD, MPH, FIDSA. On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines mRNA-1273, Moderna’s authorized WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
DR. JOHN G. BARTLETT LOOKS BACK ON AIDS: A 30-YEAR By Meredith Mazzotta on May 31, 2011. Dr. John G. Bartlett when he first joined Johns Hopkins in 1980. HIV specialist and leading infectious diseases physician John G. Bartlett, MD, doesn’t mince words when you ask him about what his AIDS patients faced in the early days of the epidemic. “They were the scourge of society – peopledidn’t
WHO WE ARE | SCIENCE SPEAKS: GLOBAL ID NEWS HIV As substance use disorders rise in the midst of a pandemic, a new law is needed now to facilitate treatment. While America’s epidemic of opioid use was already a burgeoning health crisis, it has worsened markedly since the onset of the COVID-19 pandemic. COVID MULTIVALENT VACCINES FOR MULTIVARIANT VIRUSES Instead, it will be their first dose of a COVID-19 vaccine. The Jan. 28 Novavax synopsis of its 4,400-person adjuvanted protein vaccine study in South Africa included the statement (in boldtype below) that 1/3 of those enrolled had antibody evidence of a prior non-variant SARS-CoV-2 infection, and that some had been re-infected with thevariant
BIVALENT COVID VACCINES: WHEN WILL STUDIES BEGIN IN ORDER By Daniel R. Lucey MD, MPH, FIDSA. The New York Times reported Monday (Jan. 25) that: “As a precaution, Moderna has begun developing a new form of its vaccine that could be used as a booster shot against the variant in South Africa . . . Moderna said it also planned to begin testing whether giving patients a third shot of its original vaccine as a booster could help fend off newly emerging COVID VACCINES IN HIV-POSITIVE RECIPIENTS: NEED FOR MORE By Daniel R. Lucey MD, MPH, FIDSA. The Jan. 28 Novavax press release that included preliminary results from its COVID-19 vaccine Phase 2b trial in South Africa appears to contain a significant difference in efficacy between volunteers who were HIV-positive and HIV-negative. If verified, then the implications warrant sustained attention for this protein-based adjuvanted COVID-19 vaccine, CDC ANNOUNCES PUBLICATION OF TB TREATMENT TRIAL RESULTS The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed six-month regimen will inform guidelines that can significantly ease the burden of the disease on patients, their families, and health services worldwide, the U.S. Centers for Disease Control and Prevention announced WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even COVID-19: WHEN WILL FDA CONVENE AN INDEPENDENT ADVISORY By Daniel R. Lucey M.D., MPH, FIDSA. Rapidly evolving events regarding studies of monoclonal antibodies reemphasize the call first made here Oct. 19 that the U.S. Food and Drug Administration convene an outside expert advisory committee ASAP to advise on requests for Emergency Use Authorization for monoclonal antibodies against SARS-CoV-2.. On Oct. 7 Lilly announced filing HAS TESTING OF HUMANS FOR ASYMPTOMATIC AND MILD H5N8 BIRD Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. COVID-19: IN BEIJING A NEW OUTBREAK LINKED WITH LARGE Daniel Lucey, M.D. MPH, FIDSA, FACP, is an infectious diseases physician and adjunct professor of infectious diseases at Georgetown University Medical Center, a senior scholar at the Georgetown University O’Neil Institute, Anthropology Research Associate, Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health DR. JOHN G. BARTLETT LOOKS BACK ON AIDS: A 30-YEAR One thought on “ Dr. John G. Bartlett looks back on AIDS: A 30-year perspective ” William Alexander Taylor, Jr. September 4, 2015 at 1:29 am John Bartlett, I love you. I was diagnosed in 1985 at UNC. You were at Duke. You were not my doctor but you treated many of myfriends.
SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to FOUR PROBLEMS WITH THE LAB ORIGIN HYPOTHESIS OF SARS-COV-2 By Daniel R. Lucey MD, MPH, FIDSA. Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website. Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of WHO WE ARE | SCIENCE SPEAKS: GLOBAL ID NEWS Rabita Aziz covers policy and budget issues as well as global health events around DC and global health conferences for Science Speaks and is Senior Specialist in Global Health Policy for the Infectious Diseases Society of America. She represents IDSA on global health issues, including HIV, tuberculosis, and global health security. UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
COVID-19: HHS EXPLAINS “OPERATION WARP SPEED” COVID-19: HHS explains “Operation Warp Speed”. By IDSA Contributor on August 10, 2020. By Daniel R. Lucey M.D., MPH, FIDSA. On Friday, The U.S. Department of Health and Human Services posted a succinct 4-page document titled “ Explaining Operation Warp Speed .”. The summary begins by answering three questions: What is the goal ? AN ID PHYSICIAN ADDRESSES QUESTIONS ON PNEUMONIA OF Q & A: Pneumonia Outbreak in Wuhan City, China. Daniel Lucey M.D. MPH, is an infectious diseases physician and adjunct professor of infectious diseases at Georgetown University Medical Center, a senior scholar at the Georgetown University O’Neil Institute, Anthropology Research Associate, Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America DR. JOHN G. BARTLETT LOOKS BACK ON AIDS: A 30-YEARDR JOHN BARTLETTJOHN G BARTLETT SPECIALTY PRACTICEJOHN BARTLETT MD JOHNS HOPKINSJOHN BARTLETT FACEBOOKJOHN BARTLETT INDIANAJOHN BARTLETT DESIGNER By Meredith Mazzotta on May 31, 2011. Dr. John G. Bartlett when he first joined Johns Hopkins in 1980. HIV specialist and leading infectious diseases physician John G. Bartlett, MD, doesn’t mince words when you ask him about what his AIDS patients faced in the early days of the epidemic. “They were the scourge of society – peopledidn’t
SCIENCE SPEAKS: GLOBAL ID NEWS Deadline extended for you to weigh in on Science Speaks coverage Over the last 12 years the IDSA and HIVMA Science Speaks blog has witnessed and covered a world of changes in global infectious diseases research, responses and impacts. As the blog continues to FOUR PROBLEMS WITH THE LAB ORIGIN HYPOTHESIS OF SARS-COV-2 By Daniel R. Lucey MD, MPH, FIDSA. Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website. Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to31, 2019.
VARIANT B.1.617 SPREADS IN INDIA AND UK, AND ARRIVES IN US By Daniel R. Lucey MD, MPH, FIDSA. The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10.. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.”. The United States has found and reported only a small number of cases, in at least five states so far.The CDC considers B.1617 only a variant of WHO WE ARE | SCIENCE SPEAKS: GLOBAL ID NEWS Rabita Aziz covers policy and budget issues as well as global health events around DC and global health conferences for Science Speaks and is Senior Specialist in Global Health Policy for the Infectious Diseases Society of America. She represents IDSA on global health issues, including HIV, tuberculosis, and global health security. UPDATE WUHAN CORONAVIRUS 46 thoughts on “ UPDATE Wuhan coronavirus – 2019-nCoV Q&A #6: An evidence-based hypothesis ” Luther Rhodes January 25, 2020 at 7:06 pm. Hopefully PCR rapid diagnostic and serologic testing for 2019nCoV will be available for clinicians beyond the limited CDC/State HealthDept pathways.
SEYCHELLES REPORTS RISING CASES IN VACCINATED AND Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. VIRTUAL CROI 2021: IN OPENING TALK DR. FAUCI LOOKS AT THE One thought on “ Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19 ” Reuben March 7, 2021 at 3:14 pm. And of course both confronted by a woefully inadequate public health response that relies on a for-profit health care system designed to exclude poorer people from access tohealth care.
COVID-19: HHS EXPLAINS “OPERATION WARP SPEED” COVID-19: HHS explains “Operation Warp Speed”. By IDSA Contributor on August 10, 2020. By Daniel R. Lucey M.D., MPH, FIDSA. On Friday, The U.S. Department of Health and Human Services posted a succinct 4-page document titled “ Explaining Operation Warp Speed .”. The summary begins by answering three questions: What is the goal ? AN ID PHYSICIAN ADDRESSES QUESTIONS ON PNEUMONIA OF Q & A: Pneumonia Outbreak in Wuhan City, China. Daniel Lucey M.D. MPH, is an infectious diseases physician and adjunct professor of infectious diseases at Georgetown University Medical Center, a senior scholar at the Georgetown University O’Neil Institute, Anthropology Research Associate, Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America DR. JOHN G. BARTLETT LOOKS BACK ON AIDS: A 30-YEARDR JOHN BARTLETTJOHN G BARTLETT SPECIALTY PRACTICEJOHN BARTLETT MD JOHNS HOPKINSJOHN BARTLETT FACEBOOKJOHN BARTLETT INDIANAJOHN BARTLETT DESIGNER By Meredith Mazzotta on May 31, 2011. Dr. John G. Bartlett when he first joined Johns Hopkins in 1980. HIV specialist and leading infectious diseases physician John G. Bartlett, MD, doesn’t mince words when you ask him about what his AIDS patients faced in the early days of the epidemic. “They were the scourge of society – peopledidn’t
BLOG | SCIENCE SPEAKS: GLOBAL ID NEWS | A PROJECT OF IDSA By Antigone Barton on May 10, 2021. Science Speaks, the global infectious disease blog produced by the Infectious Diseases Society of American and its HIV Medicine Association, is seeking input from its readers on how we can best keep you posted on breaking news and analysis of infectious diseases developments around the world. SCIENCE, NOT POLITICS, MUST LEAD TO COVID VACCINE The idea that political pressure could lead FDA to alter its vaccine approval standards should send shockwaves not only through the U.S., but through global health systems as well. The rush-to-approval dynamic is not limited to FDA, however. The Chinese military began using a COVID vaccine in July, long before advanced testing wascomplete.
WHY DID THE WHO-CHINA TEAM CALL THE LAB ORIGIN HYPOTHESIS By Daniel R. Lucey MD, MPH, FIDSA. Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. . Notably, these terms of references did not even FIRST LONG-ACTING INJECTABLE TREATMENT FOR HIV REPRESENTS First long-acting injectable treatment for HIV represents an exciting step forward, should be optimized with equity, investment. Dr. Rajesh Gandhi is the Co-Director of the Harvard Center for AIDS Research and the site leader of the MGH Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit and a scientific member of the Department of Health and Human Services Panel on AS THE YEAR TO START ENDING HIV AS AN EPIDEMIC BEGAN, A 2 thoughts on “ As the year to start ending HIV as an epidemic began, a pandemic changed everything ” Ed Johnson, MD June 15, 2020 at 9:52 am. Kudos Dr Finkel for your continued efforts and insights. The late Dr George Perez (an inspiration to all of us who knew him) would be very gratified to know of your continued efforts. COVID-19: CDC REPORTS ISSUE WITH REAGENT USED IN PCR TEST This entry was posted in Covid-19/2019-nCoV, Covid-19/2019-nCoV Dr. Lucey Q&A, COVID-19 Member Posts and tagged CDC, Dr. Daniel Lucey, Novel Coronavirus, 2019-nCoV, PCR test for novel coronavirus on February 14, 2020. Post navigation ← WHO: Committee finds DRC Ebola remains a PHEIC, while international team sets Covid-19 research priorities China discloses 1,716 healthcare workers HAS TESTING OF HUMANS FOR ASYMPTOMATIC AND MILD H5N8 BIRD Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. CHINA CDC DIRECTOR ON COVID-19: “ . . . THE MARKET IS JUST The following is a guest post by Daniel R. Lucey MD, MPH, FIDSA A crucial mile marker in the marathon to understand when and where theCovid
DR. JOHN G. BARTLETT LOOKS BACK ON AIDS: A 30-YEAR One thought on “ Dr. John G. Bartlett looks back on AIDS: A 30-year perspective ” William Alexander Taylor, Jr. September 4, 2015 at 1:29 am John Bartlett, I love you. I was diagnosed in 1985 at UNC. You were at Duke. You were not my doctor but you treated many of myfriends.
GROWTH AND CHALLENGES: SOUTH AFRICA’S FIGHT AGAINST HIV The NSP, which runs until December 2011, is the most ambitious plan to fight HIV/AIDS in the world. It aims to reduce incidence by 50 percent by the end of 2011, and aims to have 80 percent of people requiring treatment on ART. Heywood explained that the South African government had not always been so responsive to the AIDS epidemic. SCIENCE SPEAKS: GLOBAL ID NEWS A PROJECT OF IDSA GLOBAL HEALTHTwitter Facebook
Contact RSS
Subscribe
In All Categories Congressional Study Tour 2014: Tanzania 114th Congress McGill Summer Institute in Infectious Diseases and Global Health Seeyasoon Transition 2017 Transition 2017 115th Congress What We’re Reading About the 2017 Transition Science funding 115th Congress Zika Ebola 116th Congress Measles Covid-19/2019-nCoV Covid-19/2019-nCoV Dr. Lucey Q&A COVID-19 Member Posts Dr. Bertha Serwa Ayi posts Dr. Kwan Kew Lai posts Uncategorized HIV/AIDS HIV Prevention Circumcision Microbicides PrEP Condoms Vaccines Syringe Exchange PMTCT Treatment as Prevention TB HIV/TB Co-infection Drug Resistance GeneXpert Prevention IPT What we’re reading HIV Research and Development TB Live Blog Archive CROI 2014 AIDS 2014 IDWeek 2014, Philadelphia HIVR4P 2014 45th Union World Conference on Lung Health CROI 2015 IAS 2015 IDWeek 2015 46th Union World Conference on Lung Health, Capetown, South Africa CROI 2016 HLM 2016 AIDS AIDS2016 AIDS 2016 TB PreConference HIV R4P 2016 IDWeek2016 47th Union World Conference on Lung Health ASTMH2016 CROI 2017 CUGH 2017 IAS 2017 IDWeek 2017 48th Union World Conference on Lung Health CROI 2018 71st World Health Assembly AIDS 2018 IDWeek2018 United Nations High-level meeting on ending TB 49th Union World Conference on Lung Health CROI 2019 CUGH 2019 World Health Assembly 2019 Global Health Security 2019 IAS 2019 IDWeek 2019 50TH UNION WORLD CONFERENCE ON LUNG HEALTH CROI 2020 AIDS 2010 – Vienna CROI2010 CUGH2009 HIV/TB DC Briefing HIV_Conference IAS_Conference_Capetown Pacific Health Summit IDSA 2010 CROI 2011 United Nations HLM on AIDS 2011 IAS2011ROME IDSA 2011 Boston ASTMH 2011 CROI 2012 2nd International Treatment as Prevention Workshop 42nd Union World Conference on Lung Health 41st Union World Conference on Lung Health 19th International AIDS Conference ID Week 2012 San Diego CROI 2013 IDWeek 2013, San Francisco AIDS VACCINE 2013 Barcelona Featured Special Series CDC Global Health Efforts Blueprint for an AIDS-free generation 113th Congress Research and Development U.S. Policy and Funding Budget Health and Human Rights 113th Congress Policy R &D Funding Our Projects 30 years of AIDS Q&As with Experts Dr. Sten Vermund Dr. Peter Small Dr. Stefano Bertozzi Dr. Caroline Ryan Dr. Kevin DeCock Dr. Anneke Hesseling Dr. Anthony S. Fauci Dr. Eric Goosby Dr. John G Bartlett Mark Dybul Dr. Wafaa El-Sadr Dr. Mel Spigelman Congressional Study Tour 2010: South Africa and Zambia Congressional Study Tour 2011: Kenya Congressional Study Tour 2013: Lusaka, Zambia, and Durban, South Africa Skip tocontent
* About
* What We Do
* Who we are
* SciSpeaks Series
* Liveblog Archives
Center for Global Health PolicyIDSA
hivma
LATEST POST
COVID-19: 100,000 DEATHS LIKELY BY MEMORIAL DAY IN THE UNITED STATES by Guest Writer | May 21, 2020 Facebook Twitter Email Share The following is a guest post by Daniel R. Lucey MD, MPH, FIDSA As of May 20, 2020 more than 93,000 deaths in people laboratory-confirmed to have COVID-19 have been reported in the United States and more than 1.5 million persons have tested positive for SARS-CoV-2. All 50 states have now begun partially reopening. ItMore »
RECENT POSTS
COVID-19: DOES THE MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN HAVE IMPLICATIONS FOR VACCINES? by Guest Writer | May 20, 2020 Facebook Twitter Email Share On Saturday, the World Health Organization released a scientific brief on the multisystem inflammatory syndrome seen in children and adolescents with COVID-19. Today in Science Speaks two guest posts respond to findings around the syndrome. The following is a guest post Daniel R. Lucey M.D., MPH and Kristen R. Kent, MPhil. Since April 26England,
More »
COVID-19 CHAMELEON: HAS KAWASAKI SYNDROME BEEN LINKED TO A VIRAL ILLNESS ALL THIS WHILE?by Guest Writer |
Facebook Twitter Email Share On Saturday, the World Health Organization released a scientific brief on the multisystem inflammatory syndrome seen in children and adolescents with COVID-19. Today in Science Speaks two guest posts respond to findings around the syndrome. The following is a guest post by Bertha Serwa Ayi, M.D., FACP, FIDSA, MBA During a World Health Organization briefing,More »
LONG-ACTING INJECTED HIV PREVENTION EFFECTIVE AND SAFE, HPTN 083 TRIALDATA SHOWS
by Antigone Barton | May 18, 2020 Facebook Twitter Email Share Amid unprecedented challenges to routine healthcare access, trial results mark a first for a critically needed HIV prevention measure An investigational drug administered by injection every eight weeks has been found to be effective and safe in preventing HIV infection among men who have sex with men and transgender women who have sexwith men,
More »
More Recent Posts »FEATURED
*
COVID-19: ROLE OF SUPERINFECTIONS IN NOVEL CORONAVIRUS DEATHS HIGHLIGHTS URGENT NEED FOR SUSTAINABLE DEVELOPMENT OF NEW ANTIBIOTICS*
COVID-19: THE VIRUS ARRIVES IN WAR-TORN YEMEN WHERE HEALTH CARE IS CHALLENGED AND HAND-WASHING IS HARD TO ACHIEVE*
COVID-19: IN MARYLAND AND ACROSS AMERICA, DISPARATE OUTCOMES SHOW IMPACTS OF INEQUITIES*
COVID-19: REMBRANDT’S BELSHAZZAR’S FEAST IN A TIME OF CHIAROSCURO2020
*
COVID-19: THE HIV RESEARCH ADVOCACY MOVEMENT OFFERS LESSONS*
COVID-19: ROLE OF SUPERINFECTIONS IN NOVEL CORONAVIRUS DEATHS HIGHLIGHTS URGENT NEED FOR SUSTAINABLE DEVELOPMENT OF NEW ANTIBIOTICS*
COVID-19: THE VIRUS ARRIVES IN WAR-TORN YEMEN WHERE HEALTH CARE IS CHALLENGED AND HAND-WASHING IS HARD TO ACHIEVE* 1
* 2
* 3
* 4
* 5
LIVE BLOG ARCHIVE
*
HIV/AIDS Implementers Conference, Windhoek, Namibia.*
48th Union World Conference on Lung Health*
9th International AIDS Society Conference on HIV Science*
2017 Conference on Retroviruses and Opportunistic Infections, Seattle*
65th Annual Meeting of the American Society of Tropical Medicine andHygiene, Atlanta
*
47th Union World Conference on Lung Health, Liverpool, England*
IDWeek Meeting, New Orleans*
HIV Research for Prevention Conference, Chicago*
International AIDS Conference, Durban, South Africa*
United Nations High Level Meeting on HIV/AIDS, New York*
23rd Conference on Retroviruses and Opportunistic Infections, Boston*
46th Union World Conference on Lung Health, Capetown, South Africa*
IDWeek Meeting, San Diego*
International AIDS Conference, Vancouver, Canada*
22nd Conference on Retroviruses and Opportunistic Infections, Seattle*
45th Union World Conference on Lung Health, Barcelona, Spain*
HIV Research for Prevention Conference, Cape Town, South Africa*
IDWeek 2014, Philadelphia*
20th International AIDS Conference, Melbourne, Australia*
21st Conference on Retroviruses and Opportunistic Infections, Boston*
AIDS Vaccine Conference 2013, Barcelona*
IDWeek 2013, San Francisco*
20th Conference on Retroviruses and Opportunistic Infections*
IDWeek 2012
*
19th Annual International AIDS Conference held in Washington, DC.*
2nd International Treatment as Prevention Workshop, Vancouver*
The 19th annual Conference on Retroviruses and Opportunistic Infections, Seattle.*
The 60th Annual Meeting of the American Society of Tropical Medicineand Hygiene.
*
The 42nd Union World Conference on Lung Health, Lille, France.*
The Infectious Diseases Society of America's 49th Annual Meeting.*
The 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Rome.*
Conference on Retroviruses and Opportunistic Infections, Boston.*
41st Union World Conference on Lung Health, Berlin, Germany.*
IDSA Annual Meeting, Vancouver*
The 18th International AIDS Conference, Vienna.*
Center for Global Health Policy and GHC Briefing on HIV/TB Coinfection, Washington, DC*
Conference on Retroviruses and Opportunistic Infections, San Francisco*
Consortium of Universities for Global Health Annual Meeting,Washington D.C.
*
2009 International AIDS Conference, Cape Town*
Pacific Health Summit, Seattle, Washington.*
HIV/AIDS Implementers Conference, Windhoek, Namibia.*
48th Union World Conference on Lung HealthPrevious Next
Click above for a video on our Congressional study tour to Africa, andclick here
to read more.
HIV
LONG-ACTING INJECTED HIV PREVENTION EFFECTIVE AND SAFE, HPTN 083 TRIALDATA SHOWS
Amid unprecedented challenges to routine healthcare access, trial results mark a first for a critically needed HIV prevention measure An investigational drug administered by injection everyTUBERCULOSIS
LOCKDOWNS DUE TO COVID-19 PROJECTED TO STALL TB DETECTION AND TREATMENT LEADING TO INCREASED INCIDENCE, DEATHS GLOBALLY OVER NEXTFIVE YEARS
While stay-in-place and physical distancing measures to control the spread of COVID-19 are projected to also slow the spread of other illnesses, lockdowns prompted by that RESEARCH & DEVELOPMENT COVID-19: THE HIV RESEARCH ADVOCACY MOVEMENT OFFERS LESSONS What we have learned from HIV can guide responses to COVID-19 that are innovative, effective and inclusive, and can help end the pandemic faster The followingPOLICY
MAKE ADOLESCENT AND YOUTH REPRODUCTIVE HEALTH PROGRAMS RESPONSIVE TO NEEDS WITH BETTER DATA The following is a guest post by Bridgit Adamou, MPH, MEASURE Evaluation Young people suffer disproportionately from negative reproductive health outcomes, including acquiring HIV and otherCALENDAR
May 2020
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Apr
NEWS & RESOURCES
* Elizabeth Glaser Pediatric AIDS Foundation * Global Health Policy* IAVIReport
* IRMA
* StopTB
* Stronger Together
* Clearinghouse on Male Circumcision * Kaiser Family Foundation Global Health Policy * AVAC Global Advocacy for HIV Prevention * Treatment Acton Group * amfAR The Foundation for AIDS Research* PrEPWatch
* HIV Vaccine Trials NetworkBLOGROLL
* Impatient Optimists* Poverty Matters
* RESULTS Blog
* IAS Blog
* TB R&D Matters Blog* USAID Impact Blog
* Erasing 76 Crimes
* Health GAP Blog
* Breakthroughs Blog * Frontline Health Workers Blog* ONE Blog
* Treatment Action Group Blog * Council for Global Equality Blog * Elizabeth Glaser Pediatric AIDS Foundation Blog* Humanosphere
* I-MAK Blog
Contact Us: Infectious Diseases Society of America - 4040 Wilson Blvd, Suite 300, Arlington, VA 22203 - (p) 703-740-4955 (fax) 1-866-536-6638 - globalhealth@idsociety.org - www.idsaglobalhealth.orgStaff Login
✓
Thanks for sharing!
Facebook Twitter Email Pinterest LinkedIn Reddit WhatsApp Gmail Telegram Pocket Mix Tumblr Amazon Wish ListAOL Mail Balatarin
BibSonomy Bitty Browser Blinklist Blogger BlogMarks Bookmarks.fr Box.net Buffer Care2 News CiteULike Copy Link Design Float Diary.Ru Diaspora Digg Diigo Douban Draugiem DZone Evernote Facebook Messenger Fark Flipboard Folkd Google Bookmarks Google Classroom Hacker News Hatena Houzz Instapaper Kakao Kik Kindle It Known Line LiveJournal Mail.Ru Mastodon Mendeley Meneame MeWe Mixi MySpace Netvouz Odnoklassniki Outlook.com Papaly Pinboard Plurk Print PrintFriendly Protopage Bookmarks Pusha Qzone Rediff MyPage Refind Renren Sina Weibo SiteJot Skype Slashdot SMS StockTwits Svejo Symbaloo Bookmarks Threema Trello Tuenti Twiddla TypePad Post Viadeo Viber VK Wanelo WeChat WordPress Wykop XING Yahoo MailYoolink Yummly ____
AddToAny
Facebook Twitter Email Pinterest LinkedIn Reddit WhatsAppGmail
Email Gmail AOL Mail Outlook.comYahoo Mail
More…
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0